Individualized Statin Benefit for Determining Statin Eligibility in the Primary Prevention of Cardiovascular Disease
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Background—: Current guidelines recommend statins in the primary prevention of cardiovascular disease on the basis of predicted cardiovascular risk without directly considering the expected benefits of statin therapy based on the available randomized, controlled trial evidence. Methods and Results—: We included 2134 participants representing 71.8 million American residents potentially eligible for statins in primary prevention from the National Health and Nutrition Examination Survey for the years 2005 to 2010. We compared statin eligibilities using 2 separate approaches: a 10-year risk-based approach (≥7.5% 10-year risk) and an individualized benefit approach (ie, based on predicted absolute risk reduction over 10 years [ARR 10 ] ≥2.3% from randomized, controlled trial data). A risk-based approach led to the eligibility of 15.0 million (95% confidence interval, 12.7–17.3 million) Americans, whereas a benefit-based approach identified 24.6 million (95% confidence interval, 21.0–28.1 million). The corresponding numbers needed to treat over 10 years were 21 (range, 9–44) and 25 (range, 9–44). The benefit-based approach identified 9.5 million lower-risk (<7.5% 10-year risk) Americans not currently eligible for statin treatment who had the same or greater expected benefit from statins (≥2.3% ARR 10 ) compared with higher-risk individuals. This lower-risk/acceptable-benefit group includes younger individuals (mean age, 55.2 versus 62.5 years; P <0.001 for benefit based versus risk based) with higher low-density lipoprotein cholesterol (140 versus133 mg/dL; P =0.01). Statin treatment in this group would be expected to prevent an additional 266 508 cardiovascular events over 10 years. Conclusions—: An individualized statin benefit approach can identify lower-risk individuals who have equal or greater expected benefit from statins in primary prevention compared with higher-risk individuals. This approach may help develop guideline recommendations that better identify individuals who meaningfully benefit from statin therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
A New Initiative on Precision Medicine
Collins, F. S., & Varmus, H. (2015) · New England Journal of Medicine · doi:10.1056/nejmp1500523 · Cited by 5,202
2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk
Goff, D. C., Lloyd-Jones, D. M., Bennett, G., Coady, S., D’Agostino, R. B., Gibbons, R., Greenland, P., Lackland, D. T., Levy, D., O’Donnell, C. J., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.005 · Cited by 4,945
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Self-citationGoff, D. C., Lloyd-Jones, D. M., Bennett, G., Coady, S., D’Agostino, R. B., Gibbons, R., Greenland, P., Lackland, D. T., Levy, D., O’Donnell, C. J., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437741.48606.98 · Cited by 3,697
Collaborators, C. T. T. (. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60367-5 · Cited by 2,833
Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis
Fellström, B. C., Jardine, A. G., Schmieder, R. E., Holdaas, H., Bannister, K., Beutler, J., Chae, D.-W., Chevaile, A., Cobbe, S. M., Grönhagen-Riska, C., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810177 · Cited by 2,036
Statins for the primary prevention of cardiovascular disease
Taylor, F., Huffman, M. D., Macedo, A. F., Moore, T. H., Burke, M., Davey Smith, G., Ward, K., Ebrahim, S., & Gay, H. C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004816.pub5 · Cited by 1,934
Research works printed but not linked: 24
- 10.1056/NEJMoa1315665 · DOI · Paper page
- 10.1161/CIRCULATIONAHA.115.016846 · DOI · Paper page
- 10.1016/j.jacc.2015.07.066 · DOI · Paper page
- 10.1016/j.jacc.2014.12.028 · DOI
- 10.1001/jama.2013.276529 · DOI
- 10.1001/jama.2015.6822 · DOI · Paper page
- 10.1093/eurheartj/ehu004 · DOI · Paper page
- 10.1136/bmj.g3047 · DOI
- 10.1016/j.jacl.2014.08.004 · DOI
- 10.1093/eurheartj/ehv340 · DOI · Paper page
- 10.1001/jama.2015.3595 · DOI · Paper page
- 10.1093/clinchem/18.6.499 · DOI · Paper page
- 10.1056/NEJM199511163332001 · DOI · Paper page
- 10.1016/S0140-6736(03)12948-0 · DOI · Paper page
- Johnson CL, Paulose-Ram R, Ogden CL, Carroll MD, Kruszon-Moran D, Dohrmann SM, Curtin LR. National health and nutrition examination survey: analytic guidelines, 1999–2010. Vital Health Stat 2. 2013:1–24.
- 10.1371/journal.pone.0101717 · DOI · Paper page
- 10.1016/j.amjcard.2014.07.076 · DOI
- 10.1016/j.jacc.2009.12.057 · DOI
- 10.1016/j.jacc.2012.09.016 · DOI
- 10.1161/CIRCULATIONAHA.114.012477 · DOI · Paper page
- 10.1016/S0140-6736(14)61994-2 · DOI · Paper page
- 10.1016/S0140-6736(11)60784-8 · DOI · Paper page
- 10.1016/j.jacc.2015.02.025 · DOI · Paper page
- 10.1001/jama.2015.6177 · DOI
Cited by
Anderson, T. J., Grégoire, J., Pearson, G. J., Barry, A. R., Couture, P., Dawes, M., Francis, G. A., Genest, J., Grover, S., Gupta, M., et al. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.07.510 · Cited by 1,173
Self-citationPearson, G. J., Thanassoulis, G., Anderson, T. J., Barry, A. R., Couture, P., Dayan, N., Francis, G. A., Genest, J., Grégoire, J., Grover, S. A., et al. (2021) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2021.03.016 · Cited by 843
Self-citationQuantifying importance of major risk factors for coronary heart disease
Pencina, M. J., Navar, A. M., Wojdyla, D., Sanchez, R. J., Khan, I., Elassal, J., D’Agostino, R. B., Peterson, E. D., & Sniderman, A. D. (2019) · Circulation · doi:10.1161/circulationaha.117.031855 · Cited by 247
Self-citationNdumele, C. E., Rodriguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M., Bangalore, S., Bozkurt, B., Breathett, K., Clarke, S. L., et al. (2026) · JACC · doi:10.1016/j.jacc.2026.03.056 · Cited by 90
Sathiyakumar, V., Park, J., Quispe, R., Elshazly, M. B., Michos, E. D., Banach, M., Toth, P. P., Whelton, S. P., Blumenthal, R. S., Jones, S. R., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.032463 · Cited by 58
Metadata
- Authors
- Thanassoulis, G., Williams, K., Altobelli, K. K., Pencina, M. J., Cannon, C. P., & Sniderman, A. D.
- Venue
- Circulation
- Published
- 2016-04-19
- Volume
- 133
- Issue
- 16
- Pages
- 1574-1581
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2290361157
- Cited by
- 85
- References
- 15
- FWCI
- 15.93
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Individualized Statin Benefit for Determining Statin Eligibility in the Primary Prevention of Cardiovascular Disease. https://app.cochat.ai/papers/10.1161/circulationaha.115.018383
- The paper
- Thanassoulis, G., Williams, K., Altobelli, K. K., Pencina, M. J., Cannon, C. P., & Sniderman, A. D. (2016). Individualized Statin Benefit for Determining Statin Eligibility in the Primary Prevention of Cardiovascular Disease. Circulation. https://doi.org/10.1161/circulationaha.115.018383
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.